Advances in genomic sequencing are transforming healthcare, making it possible to identify diseases earlier, improve diagnostics and support more personalised treatments.

In this edition of Amati Insights, Amati fund managers Mikhail Zverev and Graeme Bencke discuss how falling sequencing costs, advances in clinical diagnostics and the increasing use of genomic data are creating new opportunities across healthcare. The conversation explores developments in cancer detection, liquid biopsy testing, rare disease diagnosis and precision medicine, as well as the companies helping to drive the next phase of growth in the genomics industry.